Imagine having a high-tech smoke detector for viruses that works not just in hospitals, but at airports and farms. It's paired with a digital crystal ball that uses AI to predict where the next outbreak might start by watching how viruses change. Together, they act as an early warning system to stop a local infection from becoming a global crisis.
Current pandemic responses are slowed by a lack of rapid, integrated testing and predictive modeling. This gap leads to delayed decision-making and an inability to predict where animal viruses will jump to humans.
["PANPOC: A low-cost portable device for detecting respiratory RNA viruses in humans, animals, and environment.", "PANRISK: An AI/ML platform that predicts zoonotic spillover risks and outbreak patterns using genomic data."]
If you are a medical device manufacturer dealing with slow lab turnaround times — this project developed PANPOC, a low-cost point-of-care instrument that rapidly detects respiratory RNA viruses. This allows for immediate testing in hospitals and GP clinics.
If you are an airport operator dealing with the risk of imported viral outbreaks — this project developed portable PANPOC equipment that can be validated at border controls. This enables rapid screening of travelers to prevent disease spread.
If you are a veterinary authority dealing with animal-to-human virus spillover — this project developed PANRISK, an AI platform that predicts the risk of animal pathogens drifting to infect humans. This allows for targeted surveillance in specific areas.
Based on available project data, the PANPOC system is specifically designed to be a low-cost point-of-care system, though exact pricing is not listed.
The project includes 3 industry partners and plans for EU-wide implementation guidelines, suggesting a path toward industrial scaling.
Based on available project data, specific licensing terms are not provided, but the project follows FAIR principles for data management.
The project period runs from 2024-01-01 to 2028-12-31, indicating a multi-year development and validation cycle.
PANRISK integrates genomic and epidemiological data from public databases as well as proprietary results from partners.
The consortium is diverse, comprising 21 partners across 10 countries. It features a balanced mix of 6 universities, 6 research organizations, and 6 'other' entities, supported by 3 industry partners. With a 14% industry ratio and 1 SME, the project is heavily research-driven but maintains a clear link to commercial application through its industry members.
Contact Kobenhavns Universitet in Denmark
Contact us to explore licensing opportunities for PANPOC and PANRISK.
